A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy  by Hughes, D. & Cockerell, O.C.
Seizure 1996; 5:89-95 
A cost minimization study comparing vigabatrin, 
lamotrigine and gabapentin for the treatment of 
intractable partial epilepsy 
D. HUGHES* & O.C. COCKERELLf 
*Department of Economics, City University, London, and f The National Hospital for Neurology and 
Neurosurgery, London, U.K. 
Epilepsy is one of the commonest of the serious neurological disorders. The total economic burden of epilepsy in 
the United Kingdom has been estimated to be £1930 m, with around £32 m spent on antiepileptic drug therapy 
alone. Despite the high level of expenditure on drug therapy for epilepsy there is very little information regarding 
the relative cost-effectiveness of the different drugs available. It is important to establish the relative 
cost-effectiveness of therapies to provide decision makers with the information ecessary to allocate resources in a 
rational manner and thus achieve the highest benefit for available resources. In this study the cost-effectiveness of 
lamotrigine, vigabatrin and gabapentin was estimated by a cost minimization analysis for the first year of drug 
therapy using data based on published studies. In general, there was little difference between the initial direct costs 
of treatment, however, the fewer side-effects associated with gabapentin is reflected in the lower total costs of 
treatment in the first year resulting in savings of £18.52 per patient compared with lamotrigine and £47.18 
compared with vigabatrin. Based on incidence data estimates this translates to estimated irect cost savings to the 
UK of between £166 680 and £424 620 per annum. 
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INTRODUCTION 
The prevalence of active epilepsy in the United 
Kingdom (UK) is between 4-5/1000 ~'2. The total 
annual economic burden of epilepsy has been 
estimated at £1930m per annum, with £32m 
spent on antiepliepsy drug therapy alone 3. Desp- 
ite the high level of expenditure on drug therapy 
for epilepsy there is little, if any, information 
regarding the relative cost-effectiveness of the 
available drug therapies. 
Expenditure on any treatment or therapy 
means that these resources cannot be used 
elsewhere, therefore benefit is forgone from an 
alternative treatment. This is the notion of 
opportunity cost in economics 4. Therefore it is 
important to identify the most cost-effective 
forms of treatment in order to make the best use 
of available resources. There has recently been a 
rapid expansion in the number of new antiepilep- 
tic drugs (AEDs) to treat patients with intractable 
epilepsy with the introduction of vigabatrin, 
lamotrigine and gabapentin. These AEDs are 
emerging as the main adjunctive treatments for 
patients who have failed combinations of the 
more established antiepileptic drugs. Studies 
comparing the relative cost-effectiveness of the 
new AEDs will aid clinicians and health care 
planners to decide on their efficient utilization. 
In order to pursue the objective of benefit 
maximization a means of evaluating both the 
costs and benefits associated with resources used 
is required. Economic evaluation compares the 
costs and outcomes enabling the relative merits of 
alternative uses of resources to be considered. In 
this study we carried out a cost minimization 
analysis to compare the relative costs of vigabat- 
rin, lamotrigine, and gabapentin as add-on 
therapy in patients with intractable partial seiz- 
ures. Cost-minimization analysis considers only 
the costs of interventions and requires that the 
interventions under consideration have equal 
effectiveness, usually measured in terms of 
medical outcomes or natural units of health 
output associated with the intervention. This 
enables us to consider the relative costs and 
effects of treatment and to provide results in 
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terms of the potential cost savings associated with 
switching to the most cost-effective therapy. 
METHOD 
In the absence of head to head trials the available 
evidence on the effectiveness of lamotrigine, 
vigabatrin and gabapentin is inconclusive, that is 
there is significant overlap in the efficacy ranges 
such that they cannot be shown to differ 5-~7. On 
this basis we have assumed equal efficacy and 
therefore have undertaken a cost minimization 
analysis. 
The target population in this study is patients 
with intractable partial epilepsy over the age of 12 
years. 
Costs fall into three broad areas; direct costs of 
therapy and costs of side-effects; indirect costs, 
such as production losses associated with illness; 
and intangible costs such as psychological costs of 
illness. In our main analysis we will concentrate 
on the direct costs of therapy and the treatment of 
side-effects in the first year of drug therapy. Data 
were not available in subsequent treatment years. 
We will consider indirect costs in a separate 
section but will not include them in the main 
results. Intangible costs were not measured. 
There are several perspectives that can be 
taken when considering costs; society's, the public 
sector, the health service. Society's perspective 
suggests that all costs should be included regard- 
less of upon which budget they fall. The health 
service perspective would only consider those 
costs which fall on the health service budget as 
relevant. We will only consider the costs that fall 
directly on the National Health Service (NHS) 
budget in our main analysis. Consequently our 
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Table 2: Direct costs of existing drug therapies 
Drug Cost* 
Carbamazepine £96.14 
Phenytoin £23.13 
Sodium valproate £175.75 
Phenobarbitone £7.86 
Primidone £22.61 
Clonazepam £240.63 
Ethosuximide £157.06 
Clobazam £96.36 
* Average annual cost 2°. 
results will underestimate the full costs of 
treatment, nonetheless they give an indication of 
the financial implications to the NHS of the three 
therapies. 
Costs were identified, where possible, from 
published or publicly available data. The costs 
used are presented in 1995 prices and are shown 
in Tables 1 and 2. 
There are three main tasks to enable the costs 
of the three therapies to be established. First, we 
need to identify the treatment pathways and 
side-effect profiles. Second, we need to quantify 
resource use associated with each pathway. 
Finally, we must attach costs to this resource use. 
The treatment pathways were identified as far 
as possible with reference to standard practice ~8. 
These are shown in Tables 3 and 4. 
The side-effect profiles of each drug were 
estimated from published studies TM. The side- 
effects were divided into minor and major 
side-effects. Minor side-effects were defined as 
those which did not lead to serious morbidity or 
mortality but did lead to general practitioner 
(GP) consultation in all cases and we estimated 
that this would lead to specialist referral in 1% of 
Table 1: Direct costs of procedures 
Procedure Cost 
Hospital inpatient* (per day) 
Neurology £240 
Dermatology £152 
General Medicine £164 
Psychiatry £139 
A&E £284 
Hospital outpatient* 
Neurology £27 
A&E £38 
Investigation t 
EEG £73 
CT £162 
MRI:I: £215 
Blood levels £11 
G P consultation§ £8.74 
*35, t27, :1:36, §37. 
Table 3: Standard resource utilisation for all patients with 
active epilepsy* 
Resource Frequency % of 
used per annum patients 
Specialist 1-5 34 
out-patient visit 
GP visit Nil 13 
1-4 51 
5-12 34 
Drug levels 1-21" 62 
EEG 1 55 
CT 1 23 
MRI 1 5 
A&E visit 1-2 18 
3-5 2 
In-patient stay 1 9 
* See reference2°; 1" five times per annum for patients on 
lamotrigine. 
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Table 4: Percentage of patients on existing drug therapy 
Drug % of patients 
Carbamazepine 33 
Phenytoin 43 
Sodium Valproate 29 
Phenobarbitone 17 
Primidone 6 
Clonazepam 2 
Ethosuximide 2 
Clobazam 2 
patients. This was based on the established 
referral patterns of GPs to specialist 
neurologists 19. Major side-effects were defined as 
those which led to withdrawal from therapy. The 
effects of each major side-effect were 
extrapolated from published data 2°. The side 
effects and the assumptions used are summarized 
below. 
Major side-effects with lamotrigine occur in 
9-15% of patients 5'9-1L25. Fifty per cent of this 
number is due to poor seizure control. Of these, 
5% may be admitted to hospital (5 days), 
requiring electroencephalography (EEG), 
computerized tomography (CT), and blood 
levels. The other 50-80% see a GP once, and 
50-30% see a specialist once. Forty-five percent 
of these are for skin rashes. Of these, 4-5% may 
require admission to hospital (5 days), for blood 
level estimations. The other 50-80% see a GP 
once, and 30-50% see a specialist once. Five 
percent of the others see a GP (due to insomnia, 
headache, diplopia), and 0.5-1% see a specialist 
for CT, EEG, and blood levels. 
Major side-effects of vigabatrin occur in 6-15% 
of patients 7"8'2~-23. Fifty per cent are behavioural 
disturbances. Of these, 50% require hospital 
admission (5 days), including EEG, CT, and 
blood levels of other AEDs. The other 50% of 
patients have other side-effects: mainly decreased 
consciousness and gastrointestinal reactions. Of 
Table 5: Drug costs 3a* 
Lamotrigine 
25 mg £19.97 
50 mg £33.95 
100 mg £58.57 
200 mg £99.56 
Vigabatrin 
100 tabs 
500 mg £44.85 
Gabapentin 
100 tabs 
100 mg £22.86 
300 mg £53.00 
400 mg £61.33 
* Doses costs for 56 tablets. 
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these 50% require hospital admission including 
EEG, CT, and blood levels of other AEDs. 
Major side-effects with gabapentin occur in 
3-7% of patients 6J2-15'24. All withdrawals are due 
to CNS side effects: somnolence, ataxia, dizziness, 
fatigue, nausea, or abnormal thinking. A GP 
consultation is required in 3-7%, and in 50%, a 
specialist consultation is necessary. Of these, 
4-5% may require admission to hospital (5 days) 
to undergo CT, EEG, and blood levels. 
The manufacturers' titration schedules were 
used for the dosage increments. The average daily 
doses were based on the most commonly 
prescribed average doses 26. These were 1200 mg 
for gabapentin, 200mg for lamotrigine, and 
2000 mg for vigabatrin. The drug costs used are 
shown in Table 5. 
The indirect costs were calculated assuming 
labour force participation rate for individuals 
with epilepsy of 35% 27 and 72% 3. We assumed a
participation rate of 53% which is the midpoint of 
the estimates. We took the average arnings from 
Department of Employment data as £326 per 
week 2s. This gave an adjusted daily wage of 
£34.88. 
RESULTS 
Direct costs 
The unit costs of each of the treatments and 
interventions associated with treatment pathways 
and adverse vents are presented in Tables 6-10. 
Of the three therapies vigabatrin is the least 
costly in terms of direct costs of therapy. 
However, when the costs of side-effects are taken 
into account gabapentin is the least costly, 
resulting in savings of £18.52 over lamotrigine and 
£47.18 over vigabatrin in the first year of use. The 
overall costs are shown in Table 11. 
Potential annual cost savings to the UK 
The annual pool of patients with intractable 
epilepsy who are suitable for one of the new drugs 
has been estimated to be 9000 new patients per 
annum, with a backlog of 82 000 patients 29. The 
total financial cost savings to the NHS in the first 
year of treating new patients with gabapentin 
would be £166 680 over lamotrigine and £424 620 
over vigabatrin per annum in the first year of use. 
If all the existing 82 000 patients with intractable 
epilepsy were treated with gabapentin this would 
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Table 6: Drug costs per day and per annum 
Titration schedule Cost per day Annual cost 
Lamotrigine 
week 1-2 50 mg/day £0.61 
week 3-4 100 mg/day £1.04 
week 5-52 200 mg/day £1.78 £627.39 
Vigabatrin 
week 1-52 2 g/day £1.79 £654.81 
Gabapentin 
day 1 300 mg/day £0.53 
day 2 600 mg/day £1.06 
day 3 900 mg/day £1.59 
day 4-365 1200 mg/day £1.84 £669.22 
Table 7: Costs of standard treatment paths 
Procedure Lamotrigine Vigabatrin Gabapentin 
Drugs £627.39 £654.81 £669.22 
Existing drugs £106.18 £106.18 £106.18 
Specialist £45.90 £45.90 £45.90 
GP £36.40 £36.40 £36.40 
Drug monitoring £61.19 £18.36 £18.36 
EEG £40.15 £40.15 £40.15 
CT £37.26 £37.26 £37.26 
MRI £10.75 £10.75 £10.75 
A&E £13.30 £13.30 £13.30 
Inpatient £108 £108 £108 
Total £1086.83 £1071.11 £1085.52 
lead to a saving of £1 518 640 over lamotrigine 
and £3 868 760 over vigabatrin. 
Indirect costs 
The indirect costs of treatment are production 
losses associated with the illness itself or resulting 
from treatment. We assumed that where hos- 
pitalization was required this would result in the 
same number of days lost production, i.e. if a 
five-day stay in hospital was required this would 
result in five lost working days. Therefore the 
estimates of indirect costs are conservative. The 
results are presented in Table 12. 
Sensitivity analysis 
Midpoint estimates for the incidence of adverse 
events and interventions required for standard 
treatment pathways were used. If we take the low 
values for these estimated incidence rates then 
the cost savings associated with gabapentin are 
£20.70 over lamotrigine and £20.23 when com- 
pared with vigabatrin. If we use the high values 
the cost savings are £16.32 and £74.12 over 
lamotrigine and vigabatrin, respectively. There- 
fore the results appear to be robust to changes in 
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Table 8: Incidence of side-effects and costs of treatment for 
lamotrigine 
Side-effect Incidence Expected 
treatment cost* 
Minor 
Somnolence 21.5% £4.78 
Fatigue 13.5% £3.07 
Dizziness 23.5% £5.18 
Headache 12% £2.91 
Ataxia 11.5 % £2.54 
Otherst 3% £0.67 
Major 
Poor seizure control 6% £5.39 
Skin rashes 5.4% £2.82 
Others:~ 0.6% £0.02 
Total cost £27.38 
* Costs calculated on the basis of incidence and probability of 
requiring treatment, t Non-specified, ~t Insomnia, headache, 
diplopia. 
Table 9: Incidence of side-effects and costs of treatment for 
vigabatrin 
Side-effect Incidence Expected 
treatment cost 
Minor 
Somnolence 16.25% 
Fatigue 14% 
Others* 4% 
Major 
Behavioural 5.25% 
Otherst 5.25% 
Total cost 
£2.40 
£3.18 
£0.23 
£37.67 
£27.98 
£71.46 
* Dizziness, ataxia, headache, nausea, diplopia, weight gain, 
confusion, insomnia, memory impairment, t Decreased 
consciousness, gastrointestinal reactions. 
the assumptions regarding incidence of 
interventions and side-effects. 
If we alter the assumptions regarding the 
maintenance dosage level however the results 
appear less robust. If we take the lower and upper 
limits for the possible maintenance dose levels 
(lamotrigine ranging from 75 to 300mg, 
vigabatrin ranging from 1500 to 4000mg and 
gabapentin ranging from 1200 to 2400 mg), these 
give us a range of costs for lamotrigine of 
£805.97-£1517.82, vigabatrin of £910.82- 
£1786.94 and gabapentin from £1063.96- 
£1511.04. Lamotrigine appeared to be less costly 
at the lower end of the dosage levels and 
gabapentin at the higher end. 
DISCUSSION 
Our results suggest hat there may be potential 
cost savings to the NHS if new patients with 
intractable partial epilepsy are initially treated 
with gabapentin rather than the other available 
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Table 10: Incidence of side-effects and 
for gabapentin 
costs of treatment 
Side-effect Incidence Expected 
treatment cost* 
Minor 
Somnolence 24.75% £2.84 
Fatigue 12.85% £1.39 
Dizziness 17% £2.03 
Ataxia 18.5% £2.16 
Otherst 3% £0.34 
Major 
Others* 5% £1.12 
Total cost £9.87 
* Somnolence, ataxia, dizziness, fatigue, nausea, abnormal 
thinking. 
t Non-specified. 
Table 11 : Total costs of treatment of lamotrigine, vigabatrin, 
and gabapentin 
Lamotrigine Vigabatrin Gabapentin 
Standard therapy £1086.53 £1071.11 £1085.52 
Side-effects £27.38 £71.46 £9.87 
Total £1113.91 £1142.57 £1095.39 
drug therapies. The total annual cost savings of 
just treating the 'new' intractable patients was 
estimated at between £166 680 and £424 620 per 
annum. If all new patients were started on 
gabapentin the estimated cost savings are even 
more substantial. These cost savings do not 
include the private costs to individuals or the 
psychological costs, therefore they are an 
underestimate of the true costs of treatment and 
side-effects. 
We found that the indirect costs associated with 
the standard therapies were similar. However, 
this is not surprising as the standard treatment 
profiles are almost identical. As in the main 
analysis the main difference appeared in the 
indirect costs of side-effects, and with gabapentin 
the relatively low incidence of major side-effects 
requiring hospitalization and other costly 
interventions resulted in the indirect costs being 
low. The main reason for the higher cost of 
lamotrigine was the cost of anticonvulsant levels 
of phenytoin, carbamazepine and sodium 
valproate. These are required because of the 
interactions of lamotrigine with the these 
Table 12: Indirect costs of treatment of lamotrigine, 
vigabatrin, and gabapentin 
Lamotrigine Vigabatrin Gabapentin 
Standard therapy £22.74 £22.74 £22.74 
Side-effects £1.03 £10.51 £0 
Total £23.77 £33.25 £22.74 
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AEDs 3°-32. Reduced use of serum monitoring of 
lamotrigine would be associated with a lower 
cost. Current evidence indicates that the 
introduction of new AEDs leads to more, not less 
serum level monitoring 33. Of the three therapies, 
vigabatrin was the only one to have any 
significant costs associated with lost production. 
This reinforced the relative cost savings of 
gabapentin over vigabatrin. The difference 
between lamotrigine and gabapentin was 
relatively unchanged. 
The cost estimates appear obust with respect 
to the assumptions regarding the incidence of 
side-effects, but less so if the dosage levels are 
altered. However, if dosage levels have an impact 
on effectiveness it is difficult to maintain the 
assumption of equal effectiveness and a more 
sophisticated cost-effectiveness analysis would be 
required. 
It should also be stressed that the main 
assumption underpinning our findings is that 
gabapentin, lamotrigine and vigabatrin are of 
equal efficacy. This assumption is based on 
available evidence, however this evidence lacks 
any head to head trials. If it is demonstrated that 
one of these new drugs has superior efficacy this 
then would invalidate the findings of this study. 
Furthermore we assumed that the time patients 
spent on each AED is equal. If, however, an 
AED was less effective then patients would take 
it for less time, reducing the total drug costs 
associated with treatment. Also, with some of the 
AEDs, the time taken to build up to the effective 
dosages range and decide upon efficacy may be 
different. A trial of gabapentin therapy could 
conceivably take less time than lamotrigine, for 
example, thus reducing the total cost of treatment 
with gabapentin since less drug would be 
consumed. 
Finally, it is not clear whether these cost 
savings will continue after year one, most notably 
because many of the major side-effects will lead 
to withdrawal from the drug therapy and 
consequently the costs of these side-effects will 
not continue. It is probable that as gabapentin 
was associated with least side-effects in the first 
year that this would continue with more 
prolonged usage. However, this is only an 
assumption as long-term tolerability data is 
limited. 
In conclusion, this paper is one of the first 
studies to investigate the cost-effectiveness of 
antiepilepsy drug therapy for partial intractable 
epilepsy. The main short comings to this study are 
the assumptions which have to be made when 
modelling treatment paths and side-effects rather 
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than using actual patient data. The alternative 
approach to this method, which has been 
promoted ~, is to carry out economic analyses 
together with the clinical trials, but this carries 
large logistic and financial costs which are 
unlikely ever to be met by the existing AED 
development budgets. This study shows that the 
cost incurred by AEDs can still be adequately 
assessed by modelling, and that further studies to 
look at the relative cost-effectiveness of the 'new', 
and the more established AEDs, are needed to 
promote cost savings in the treatment of patients 
with refractory epilepsy. 
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